Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
| Revenue: | ||||
| Net sales | $ 93,020 | $ 59,530 | $ 183,517 | $ 258,488 |
| Cost of sales | (79,913) | (79,026) | (147,614) | (327,109) |
| Gross profit (loss) | 13,107 | (19,496) | 35,903 | (68,621) |
| Operating Expenses: | ||||
| Research and development | (2,925,355) | (2,520,992) | (11,082,764) | (8,375,896) |
| Selling, general and administrative | (3,691,507) | (2,631,027) | (10,089,252) | (7,187,535) |
| Total Operating Expenses | (6,616,862) | (5,152,019) | (21,172,016) | (15,563,431) |
| Loss From Operations | (6,603,755) | (5,171,515) | (21,136,113) | (15,632,052) |
| Other Income (Expense): | ||||
| Interest income | 10,843 | 92,094 | 113,125 | 246,880 |
| Foreign exchange transaction loss | (35) | (12,997) | (59,241) | (23,283) |
| Interest expense, including amortization of debt discount | (7,800) | (172,429) | (27,904) | (781,212) |
| Total Other Income (Expense) | 3,008 | (93,332) | 25,980 | (557,615) |
| Loss before income taxes | (6,600,747) | (5,264,847) | (21,110,133) | (16,189,667) |
| Tax benefit | 5,169,395 | 5,060,778 | ||
| Net Loss | (6,600,747) | (5,264,847) | (15,940,738) | (11,128,889) |
| Other Comprehensive Income (Loss): | ||||
| Unrealized (loss) gain from investments | (8,414) | (3,125) | (193) | 4,714 |
| Foreign currency translation gain | 2,483 | 786 | 2,595 | 765 |
| Total Other Comprehensive Income (Loss) | (5,931) | (2,339) | 2,402 | 5,479 |
| Comprehensive Loss | (6,606,678) | (5,267,186) | (15,938,336) | (11,123,410) |
| Net Loss | (6,600,747) | (5,264,847) | (15,940,738) | (11,128,889) |
| Deemed dividend as a result of warrant modification | (369,500) | (369,500) | ||
| Deemed dividend as a result of exchange of convertible note and Series C-2, D and F preferred stock, related party | (26,733,098) | (26,733,098) | ||
| Net Loss Attributable to Common Shareholders | $ (6,600,747) | $ (32,367,445) | $ (15,940,738) | $ (38,231,487) |
| Net Loss Per Common Share – Basic and Diluted (in Dollars per share) | $ (0.22) | $ (1.35) | $ (0.58) | $ (1.62) |
| Weighted Average Common Shares Outstanding – Basic and Diluted (in Shares) | 29,601,412 | 24,015,927 | 27,276,648 | 23,642,033 |
| X | ||||||||||
- Definition Deemed dividend as a result of exchange of convertible note and Series C-2, D and F Preferred Shares, related party. No definition available.
|
| X | ||||||||||
- Definition Deemed dividend as a result of warrant modification. No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of other comprehensive income (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|